HAVANA, Cuba, Dec 1 (ACN) A clinical trial called Baconao is being carried out in the province of Matanzas to measure the effects and safety of the vaccines Abdala and Mambisa as booster doses, according to Verena Muzio, clinical research director of the Center for Genetic Engineering and Biotechnology (CIGB).
Dr. Muzio explained that Baconao is a multicenter and randomized Phase II trial involving around 3,000 local Tourism and Health workers previously immunized with Abdala to evaluate the aforesaid parameters.
Once the Center for the State Control of Medicines, Equipment and Medical Devices (CECMED) approved the study on November 18, it was implemented in this province in two stages: inoculation and measurement of the immunological response 14 later.
The expert pointed out that this trial seeks to add Mambisa to the program as a booster, since the first SARS-Cov-2 immunogen in Latin America is already administered to vaccinated individuals, and with good results.
Dr. Muzio confirmed that both CIGB and AICA Laboratories have fulfilled their commitments to the country by delivering to the national health system 24 million doses of Abdala for eight million Cubans and 16 million doses to Vietnam, Nicaragua and Venezuela.
The CIGB is currently doing research on pregnant women immunized with this vaccine to establish indicators such as immune response, vaccine safety, and immunological status of their babies after birth, she said.
This analysis will serve as a precedent for a research scheduled for 2022 about Abdala’s safety and immunogenicity in children under two years of age who have not been vaccinated.
She praised the participation of the Ministry of Public Health in the massive vaccination campaign and thanked the efforts of its workers, whom she congratulated because on December 3 they will celebrate Latin American Medicine Day, in honor of Carlos Juan Finlay, discoverer of the Aedes aegypti mosquito—the vector responsible for yellow fever—-who was born on that day in 1833.
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio